PrEP use increased between 2013 and 2023, according to a research letter published online in the Journal of the American Medical Association.

“With low uptake of PrEP among the communities most impacted by HIV, this insurance coverage requirement with zero ...

Affordability and mass distribution will be critical to the success of a long-lasting injectable HIV prevention drug that has ...

From oral PrEP, to injectables, rings, and implants, this year's HIV Research for Prevention conference was all about options ...

Lenacapavir is a long-acting pre-exposure prophylaxis (PrEP) product, a treatment that works by stopping HIV from getting ...

Leerink upgraded Gilead (GILD) to Outperform from Market Perform with a price target of $96, up from $74. The stock has appreciated following ...

July 23, 2024 — Long-acting injectable cabotegravir (CAB-LA) was safe and well tolerated as HIV pre-exposure prophylaxis (PrEP) before and during pregnancy in the follow-up phase of a global ...

Indigenous communities in Latin America say they are missing out on life-saving HIV drugs due to a lack of representation.

Researchers from the HIV Prevention Trials Network (HPTN) presented results from HPTN 091 ("I Am Study") at the HIVR4P 2024 conference in Lima, Peru. The study examined the acceptability and ...

For questions about subscriptions or your Slate Plus feed, check our FAQ. Please enable javascript to get your Slate Plus feeds. We're sorry, but something went wrong ...

Now more than 40 years since the discovery of the HIV pandemic. 8 The results of this study provide reason for optimism that offering long-acting antiretroviral options for PrEP, as part of a flexible ...

The Centers for Disease Control and Prevention (CDC) has announced the five health departments that will receive federal funding to provide generic pre-exposure prophylaxis (PrEP) to prevent HIV as ...